QUT offers a diverse range of student topics for Honours, Masters and PhD study. Search to find a topic that interests you or propose your own research topic to a prospective QUT supervisor. You may also ask a prospective supervisor to help you identify or refine a research topic.
Found 6 matching student topics
Displaying 1–6 of 6 results
Reversing Epithelial Mesenchymal Plasticity with Eribulin to Enhance Therapy Response
Epithelial mesenchymal plasticity (EMP) is a highly regulated and powerful cellular process that is fundamental in embryonic development (1), which is hijacked by cancer cells for metastatic progression and therapy resistance in epithelial cancers (2). Eribulin is a microtubule-inhibiting cancer drug discovered in sea sponges and approved for 3rd line therapy in metastatic breast cancer, which was shown to reverse epithelial mesenchymal transition (EMT) (3).We hypothesise that eribulin’s reversal of EMT will sensitise breast cancer cells to other therapies and …
- Study level
- Master of Philosophy
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
Targeting a novel adaptive neovascular response of the tumour microenvironment to treat advanced prostate cancer
Prostate cancer (PCa) is a significant healthcare burden in Australia. Androgen signalling inhibition using androgen receptor (AR) antagonists is the principal systemic therapy for advanced PCa. Androgen receptors (AR) are an attractive therapeutic target due to their elevated expression in tumour epithelial cells and the retention of androgen signalling throughout the disease continuum.However, patients eventually develop resistance to treatment, and PCa cells metastasise to distant bone and visceral organs, representing an incurable stage of the disease. Understanding mechanisms that contribute …
- Study level
- PhD, Master of Philosophy, Honours
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
Developing a precision oncology workflow for Osteosarcoma treatment
Osteosarcoma (OS) is the most common malignant bone tumour that primarily affects children and adolescents. With approximately 400 diagnosed cases/year in Australia, OS has the lowest survival rate of all solid cancers and is the leading cause of cancer-related death in Queensland adolescents. Unfortunately, 3 in 4 patients will not survive longer than five years following diagnosis with metastatic OS. Clinical “one size fits all” treatment strategies results in highly variable and unacceptably poor patient responses. Shockingly, both the OS …
- Study level
- PhD, Master of Philosophy
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
- Research centre(s)
- Centre for Biomedical Technologies
Investigating the role of Neuropilin-1 in Triple-Negative Breast Cancer metastasis and chemoresistance
Triple-negative breast cancers (TNBC) are negative for Estrogen Receptor, Progesterone Receptor and HER2 expression, are clinically aggressive and are unresponsive to the available hormonal or targeted drugs used for other breast cancer subtypes, so that TNBC patients rely mainly on chemotherapy. TNBC accounts for 15-20% of all invasive breast cancer and patients have increased risk of recurrence, mortality and early metastatic progression. Thus, there is an urgent clinical need to develop improved treatment strategies for TNBC. Neuropilin-1 (NRP1) is a …
- Study level
- PhD, Master of Philosophy, Honours
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
Eribulin effects on epithelial mesenchymal plasticity and therapy response
Epithelial mesenchymal plasticity (EMP) is a highly regulated and powerful cellular process that is fundamental in embryonic development (1), which is hijacked by cancer cells for metastatic progression and therapy resistance in epithelial cancers (2). Eribulin is a microtubule-inhibiting cancer drug discovered in sea sponges and approved for 3rd line therapy in metastatic breast cancer, which was shown to block EMP (3).We hypothesise that eribulin’s reversal of EMT will sensitise breast cancer cells to other therapies and ultimately improve patient …
- Study level
- Master of Philosophy, Honours
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
Understanding capsular polysaccharide diversity is key to next generation therapies for multi-drug resistant Acinetobacter baumannii infections
Bacteriophage therapy is an attractive innovative treatment for infections caused by extensively drug resistant Acinetobacter baumannii, for which there are few effective antibiotic treatments remaining.Capsular polysaccharide (CPS) is a primary receptor for lytic bacteriophage, thus knowledge of the chemical structures of CPS produced by the species underpins the identification of suitable phage for therapeutic cocktails.As many phage depolymerases cleave a specific CPS linkage formed by either a glycosyltransferase or polymerase enzyme, characterisation of these proteins are essential.However, these remain largely …
- Study level
- PhD
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
- Research centre(s)
-
Centre for Immunology and Infection Control
Contact us
If you have questions about the best options for you, the application process, your research topic, finding a supervisor or anything else, get in touch with us today.